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Constitutive (COX-1) and inducible (COX-2) cyclooxygenase isoforms have been
detected in various mammalian tissues. Their activity is blocked by non-steroidal
anti-inflammatory drugs that may induce various side reactions. The aim of the
study was to evaluate the effects of DFU, a selective COX-2 inhibitor, on exo-
crine and endocrine pancreatic function and the immunoexpression of both
COX isoforms in maternal and foetal rat pancreases. The compound was admin-
istered to pregnant Wistar rats once daily from the 8th to the 21st day of gesta-
tion. Glucose level and amylase activity were determined in the maternal sera.
Maternal and foetal pancreases were examined histologically. Immunoexpression
of COX-1 and COX-2 was also evaluated. Both biochemical parameters, as well as
the histological structure of the pancreas were undisturbed in the dams and their
foetuses. The maternal glucose level was found to be an important factor for
foetal growth. Strong cytoplasmic COX-1 immunostaining was observed in acinar
secretory cells, whereas in islets the immune reaction was weak. Endocrine cells
also revealed strong cytoplasmic COX-2 staining in the maternal and foetal pan-
creases. Acinar cells exhibited nuclear reaction, which was strong in the foetal but
weak in the maternal pancreases. No differences in COX immunoexpression were
found between the DFU-exposed and the control groups in either mothers or
foetuses. It should be stressed that DFU administered throughout mid and late
pregnancy in rats did not change maternal or foetal pancreatic morphology or
immunoexpression of either of the main COX isoforms in the organ.
Key words: coxibs, cyclooxygenase, diabetes, foetus, glucose, NSAID,
macrosomia, pregnancy
INTRODUCTION
The two main isoforms of cyclooxygenase (COX),
namely constitutive (COX-1) and inducible (COX-2),
have been detected in various mammalian tissues
and organs. The third one (COX-3), also known as
central, has almost exclusively been detected in the
central nervous system, in particular structures in-
volved in the general sensory neuronal pathway. The
enzyme initiates prostanoid (prostaglandin, prosta-
cyclin and thromboxane) synthesis and its activity is
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inhibited by the specific reversible or irreversible COX
inhibitors. The non-selective COX inhibitors (e.g., ibu-
profen and naproxen) block both constitutive and
inducible isoforms, while the selective ones (e.g., DFU
and rofecoxib) inhibit inducible isoform only. How-
ever, in higher than therapeutic doses COX-1 inhibi-
tion could appear as well [3, 12, 24].
A number of animal and human studies have
indicated that a decrease in COX-1 activity induces
various side reactions, including gastrointestinal and
renal toxicity and others which depend on the block-
ade of the housekeeping functions of the inducible
isoform [3, 12]. However, the constitutive expres-
sion of COX-2 has also been found in some organs.
It should be noted that high expression of this iso-
form is typical of foetal organs and decreases rapid-
ly after delivery. In mature tissues the highest ex-
pression of COX-2 is characteristic of the macula
densa, pancreatic islets and some structures of the
central nervous system [12, 28, 31].
In previous studies COX-1 immunoexpression in
the pancreas has been limited to acinar secretory cells,
while COX-2 was found in secretory cells of the endo-
crine pancreatic islets and in epithelial cells of the
pancreatic ducts and smooth muscle cells of the blood
vessels of the pancreatic stroma [6, 21, 31]. On the
other hand, Zabel-Langhennig et al. [32] revealed that
both COX-1 and COX-2 isoenzymes are synthesised
in rat pancreatic acinar cells. The differences are prob-
ably secondary to methodology, since the authors
examined both isoenzymes on the mRNA level [32].
It was also reported that indomethacin, a non-selec-
tive COX-inhibitor, decreased basal, glucose- and glu-
cagon-stimulated acute insulin response [31]. Accord-
ing to Koliopanos et al. [21] pancreatic islets displayed
a variable COX-2 staining pattern, which was associ-
ated with the distribution of insulin-positive cells and
with the clinical diabetes mellitus status. In normal
insulin production or latent diabetes COX-2 immu-
noreactivity was found, whereas in diabetic patients
the COX-2 expression was decreased or absent from
the pancreatic islets.
The present study was undertaken to evaluate
the effects of DFU (i.e., 5,5-dimethyl-3-(fluorophe-
nyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone),
a selective COX-2 inhibitor, on exocrine and endo-
crine pancreatic functions and immunoexpression of
the constitutive and inducible cyclooxygenase iso-
forms in the rat pancreas during pregnancy. The data
were collected during a large scientific project un-
dertaken to evaluate the prenatal toxicity of the ex-
amined compound, and the article partially covers
foetal findings previously published in detail [8]. Since
COX-2 is expressed almost exclusively in islet paren-
chyma [3, 6, 21, 31], the influence of the maternal
glucose level on foetal and placental development
was also studied.
MATERIAL AND METHODS
The study was conducted on sexually mature al-
bino rats of the Wistar CRL:(WI)WUBR strain and
approved by the Local Bioethical Committee (guide-
line  No.372/2002).
All the animals were obtained from an accredited
breeder (Warsaw-Rembertow, Poland), and housed
and maintained in an animal care facility. On mating
days females (weight 200–250 g) were placed in cag-
es with males (5:2) for approximately 14 hours. The
following morning a vaginal smear test was performed
to determine if copulation had occurred. The day when
sperm was found was designated gestation day 1.
Sperm-positive females were randomly selected to the
drug-treated and control groups.
DFU (Merck Research Laboratory, a gift from
Merck & Co. Inc., Rahway NJ, USA; purity > 99%)
was intragastrically administered to pregnant Wist-
ar rats (n = 20/group) once daily from the 8th to the
21st day of gestation in the following doses: 0.2, 2.0
and 20.0 mg/kg/dose. Animals in the control group
(n = 20) received the Tween 80 water suspension in
a volume that corresponded to the drug-exposed
groups (10 ml/kg).
On gestation day 21 the animals were anaesthe-
tised and blood was taken from the beating heart.
The dams were sacrificed by decapitation. During the
autopsy the internal organs were removed and ex-
amined. The foetuses were removed and separated
from the placenta. The weights of the foetuses and
placentae, as well as the foetal crown-rump lengths,
were individually checked. The body mass indices (BMI)
were calculated: BMI [kg/m2] = body weight/(crown-
rump length)2. Comprehensive teratological measure-
ments and observations were performed [8].
The maternal blood was placed in standard plas-
tic test tubes, and centrifuged. The amylase and glu-
cose levels were determined using colorimetric en-
zymatic methods and commercial laboratory kits by
Cormay (Poland).
The maternal and foetal pancreatic samples were
fixed in 10% buffered formalin, embedded in paraf-
fin blocks, sectioned at 5 mm and then stained rou-
tinely with haematoxylin and eosin.
The immunohistochemical reactions for COX-1
and COX-2 were performed on 4 mm slides obtained
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from the paraffin blocks used previously for histo-
logical examination. After dewaxing and rehydration
the slides were placed for three cycles of heating in
a microwave oven (750 W) for 5 min in citrate buff-
er (0.01 M, pH 6.0) for antigen retrieval. Endoge-
nous peroxidase activity was then blocked with 3%
hydrogen peroxide for 5 min and the slides were in-
cubated for 60 min with primary mouse monoclonal
anti-human antibodies (Novocastra; Newcastle, UK)
against COX-1 (clone 12E12, dilution 1:20) and COX-2
(clone 4H12, dilution 1:200). The next step was in-
cubation with DakoEnvisionTM+/HRP, Mouse kit (Da-
koCytomation; Glostrup, Denmark) according to the
manufacturer’s directions. The specific immune reac-
tion was visualised by 3’,3-diaminobenzidine tetrahy-
drochloride (DAB) (DakoCytomation; Glostrup, Den-
mark), and finally the sections were counterstained
with Mayer’s haematoxylin. TBS buffer rinsing was
used after each step. The whole procedure was per-
formed at room temperature. In all the cases the ap-
propriate positive and negative controls were per-
formed. Sections treated in the same way but with
mouse pre-immune serum without the examined pri-
mary antibodies were used as negative controls. For
the positive COX-1 and COX-2 controls human colon-
ic mucosa and osteochondroma respectively were
applied. Before starting the immunohistochemical
study proper, the cross-reactivity with rat tissues was
verified. All the slides were evaluated, without knowl-
edge of the group treated, under a light microscope
(Olympus BX45; Tokyo, Japan).
Quantitative continuous data were compared
between the experimental groups using the Kolmo-
gorov-Smirnov test. Differences in continuous vari-
ables were evaluated by the ANOVA, ANOVA Kruskal-
Wallis and Student’s t tests. If the data were not
normally distributed, the Mann-Whitney U test was
employed. The nominal scale measures were analy-
sed by the c² test with Yates’ correction for indepen-
dence for differences among treatment groups. On
the basis of the normal glucose level, calculated as
a 95% coefficient interval (CI) of the glucose level in
the control group, the drug-exposed litters were di-
vided into three groups, those below, those over and
those at the 95% CI level. Correlations between all
the examined parameters were analysed by the
Spearman rank R test. A 0.05 level (p < 0.05) of proba-
bility was used as the criterion of significance.
RESULTS
No maternal mortality was noted in either the
drug-treated or the control groups. Maternal body
weight gain, as well as food and water intake dif-
fered insignificantly from the control group.
Except for sporadic enlargement of the intestinal
loops and a small amount of peritoneal fluid, no
other signs of gastrointestinal toxicity were found
during necropsy. However, in a few cases gastric
and intestinal injuries of varying severity, includ-
ing one deeply penetrating ulcer, were revealed
microscopically. Mild hepatic and renal abnormal-
ities were also noted during histological examina-
tion. A statistically significant decrease in foetal
body length observed in the groups exposed to
the highest dose of DFU was the only sign of de-
velopmental toxicity of the tested substance
(Fig. 1). A detailed report on the gastrointestinal,
hepatic and renal effects and foetal observations
are presented in detail elsewhere [7, 8].
In none of the drug-exposed groups was the glu-
cose level significantly altered when compared with
the controls (Table 1). However, a slight increase in
glucose level was found in the group treated with
the tested compound (Fig. 2). No significant chang-
es in amylase activity were noted.
A statistically significant negative correlation
[Spearman rank (Rs) = –0.4581] between maternal
glucose level and foetal weight was found in the
control group. A positive correlation (Rs = 0.5088)
was also revealed between foetal weight and
length. A similar but less distinct (Rs = 0.3907)
Figure 1. Relative (%; mean ± SD) body weight and length,
body mass index (BMI), as well as placental weight in group
exposed to DFU [mg/kg] when compared with the corresponding
control value (*p < 0.05 vs. control).
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correlation between both foetal parameters was ob-
served in the common group that contained all the
DFU-treated litters. However, a statistically signifi-
cant correlation (Rs = 0.2772) was only found be-
tween maternal glucose level and foetal/maternal
weight ratio. When the whole group was divided
into three, corresponding to the normal glucose level
(191.44–244.16 mmol/l) calculated as 95% of the
coefficient interval of values in the control group,
insignificant correlations between maternal and foe-
tal parameters were revealed in litters characterised
by glucose levels below or over the control values.
The only positive correlation was revealed for foetal
length and glucose level (Rs = 0.4932) in litters with
the control glucose level. In all the groups examined
a significant correlation was seen between BMI and
foetal length and/or weight. No significant correla-
tion was consistently noted between placental
weight and glucose level and amylase activity. The
only statistically significant correlation (Rs = –0.3054)
between maternal amylase activity was noted for
dam’s body weight gain in the common DFU-ex-
posed group. However, it should be stressed that
an increase in enzyme activity was found in the drug-
treated mothers with lower and higher glucose
activity (Fig. 3).
It was also shown that in the control group
a greater placental weight was found in litters ob-
tained from mothers with high body weight gain
and high glucose levels (Fig. 4A). In the DFU-treated
groups a greater placental weight was observed
in litters with low glucose levels (Fig. 4B). No sim-
ilar data were revealed for foetal weight and
length in the control groups (Fig. 4C, E). Howev-
er, a high glucose level and low maternal weight
gain predicted high foetal weight, while high foe-
tal length was observed in litters with a high
Figure 2. Relative (lg% — logarithm%; Mean ± SD) amylase ac-
tivity and glucose level in group exposed to DFU [mg/kg] when
compared with the corresponding control value.
Figure 3. Absolute amylase activity in mothers treated with DFU
with low (< 95% CI), normal (95% CI) and higher (> 95% CI) glu-
cose levels (p value vs. group with normal glucose level).
Table 1. Absolute amylase activity and glucose level in maternal sera in control and DFU-treated groups
DFU [mg/kg] Min. Max. Mean SD Median p1 p2
Amylase [IU/l] – 3249.00 11714.9 7017.11 2537.47 6948.60 – –
0.2 3493.00 11093.4 7256.22 2337.12 7313.90 0.796 0.992
2.0 3078.90 12697.2 7152.47 2835.52 7390.60 0.870 0.992
20.0 3441.70 11861.9 7214.35 2676.87 7418.10 0.824 0.992
Glucose [mmol/l] – 112.00 308.0 217.80 56.33 212.50 – –
0.2 165.00 465.0 234.05 78.34 204.50 0.499 0.899
2.0 143.00 457.0 226.60 71.54 217.00 0.684 0.899
20.0 145.00 398.0 228.45 63.97 211.00 0.645 0.899
Min. — minimum, Max. — maximum, SD — standard deviation, 1p value when compared with the control value, 2p value in the whole group exposed to DFU when com-
pared with the control value
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glucose level and a high maternal weight gain
(Fig. 4D, F).
The histological structure of the pancreas was
found to be undisturbed in all the slides examined
from the DFU-exposed and control groups, in both
mothers and foetuses (Fig. 5A, B). Strong cytoplas-
mic COX-1 immunostaining was seen in pancreatic
acinar secretory cells, whereas in the endocrine cells
of islets the immune reaction was weak (Fig. 5C, D).
Endocrine cells were strongly COX-2-positive in
the maternal and foetal organs (Fig. 5E, F). In all
the cases the staining pattern was cytoplasmic.
Figure 4. Placental (A, B) and foetal (C, D) weights [g], as well as foetal length [mm] (E, F) in relation to relative maternal body weight
gain (%) and absolute glucose level [mmol/l] in control (A, C, E) and DFU-exposed (B, D, F) groups; PW — placental weight; FW — foet-
al weight; FL — foetal length.
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Furthermore, acinar cells exhibited a nuclear reac-
tion, which was strong in foetal, while weak and
only focal in maternal pancreases. A positive reac-
tion was also observed in the epithelial cells of the
pancreatic ducts and the smooth muscle cells of
blood vessels. No differences in COX immunoexpres-
sion were found between DFU-exposed and control
groups in either mothers or foetuses.
Figure 5. Normal pancreatic morphology in maternal (A) and 21-day old foetal (B) rat exposed to DFU at a dose of 20.0 mg/kg (haema-
toxylin and eosin, lens mag. 20¥). Immunostaining for COX-1 (C, D) and COX-2 (E, F) in maternal (C, E) and 21-day old foetal (D, F) pan-
creas (DakoEnvisionTM+/HRP; C-F: lens magn. 20¥).
A
C
E F
D
B
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DISCUSSION
The study demonstrated that organ morphology
and function were undisturbed after administration
of a selective COX-2 inhibitor, in spite of the consti-
tutive expression of the inducible isoform in the pan-
creas. However, since endocrine pancreatic function
was monitored only by the glucose level and the
morphology of the islets of Langerhans, other more
sophisticated methods are desirable to confirm our
results. On the other hand, the data obtained veri-
fied previous experimental findings on the good tol-
erability of the tested compound. In the above-cited
paper by Burdan et al. [7] a good gastrointestinal,
hepatic and renal toxicological profile was demon-
strated for both pregnant and non-pregnant rats.
Since DFU is still in the pre-clinical study, no similar
human data were available in the literature. It should
also be noted that, unlike the non-selective COX in-
hibitor, DFU did not induce severe gastrointestinal
changes such as deeply penetrating ulcers, which
may result in secondary peritoneal inflammation [7].
Thus the direct effect of local inflammation as
a mechanism that may explain an insignificant in-
crease in glucose level cannot be apply [26]. Similar
results were also reported in our previous study with
another selective COX-2 inhibitor, namely DuP-697,
which did not change the morphology and immu-
noexpression of the constitutive and inducible COX
isoforms in the rat pancreas during pregnancy [5].
Biochemical tests were not performed, however.
On the other hand, an analgesic and antipyretic mix-
ture containing a non-selective COX inhibitor, pre-
pared with paracetamol, propyphenazone and caf-
feine in a constant ratio of 5:3:1, increases the amy-
lase activity in non-pregnant female rats exposed to
the highest doses of the examined drugs (0.35, 0.21
and 0.07 g/kg respectively) [4]. An insignificant decrease
in enzyme activity was noted in other groups of non-
pregnant, as well as pregnant animals that were treat-
ed with the same or lower doses of the mixture.
As was stressed in the introduction, different
pancreatic COX immunoreactivity has already been
reported in healthy and diabetic patients, as well
as after administration of COX-inhibitors [31]. The
roles of prostanoid, especially prostaglandin E2
(PGE2), and the COX-related mechanism in the aeti-
ology of diabetes and pancreatitis have already been
reported [1, 9, 10, 11, 15, 17, 23]. Histologically,
an inflammatory infiltration of the islets of Langer-
hans  is typical of type I diabetes, which is classified
as an autoimmune disease [2]. Additionally, inflam-
matory stimulators such as cytokines, liposaccha-
ride and mitogens increase an otherwise high phys-
iological expression of COX-2 in insulin-secreting
cells and secondarily initiate their cytotoxicity [3, 31].
At the same time a low physiological level of COX-1
is not significantly changed [15]. However, chronic
hyperglycaemia impairs insulin-secreting cell func-
tion and decreases the number and/or size of islets
of Langerhans in type II diabetes. This may be the
consequence of oversynthesis of interleukin 1 (IL-1)
followed by apoptosis of insulin-secreting cells [23].
The pioneer study co-ordinated by Hughes et al. [17]
indicated that recombinant human IL-1α was able
to induce PGE2 accumulation in isolated rat islets
of Langerhans at concentrations similar to those at
which the cytokine inhibits glucose-induced insulin
secretion and islet glucose oxidation. Prior studies
also showed that a high glucose concentration in-
creased COX-2 expression [26]. The data were par-
tially confirmed in mice treated with NS-398,
a selective COX-2 inhibitor, which prevented the on-
set of diabetes in mice brought on by multiple low
doses of streptozotocin [29]. Moreover, COX-2 se-
lective inhibitors such as NS-398 and SC-236 pre-
vent the destruction of insulin-secreting cells initi-
ated by IL-1 [30].
It has also been reported that COX-2 inhibition
reduces the severity of pancreatitis and pancreatitis-
associated lung injury [1, 10, 11]. With results simi-
lar to our data, Alhan et al. [1] demonstrated that
celecoxib did not change amylase activity, glucose
level or other biochemical parameters and pancre-
atic morphology in the rat. It was also found that
treatment improved lung and renal function, de-
creased the severity of pancreatic damage and nor-
malised serum levels of IL-6 in cerulean-induced pan-
creatitis in rats. Similar results were obtained in rats
with taurocholate-induced acute pancreatitis treat-
ed with parecoxib [10]. However, celecoxib-induced
acute pancreatitis and hepatitis have also been found
in humans [9].
The present study indicated that prenatal expo-
sure to COX-2 selective inhibitors may affect placen-
tal and foetal development. Previously, the dose-
dependency had been demonstrated only for foetal
length [8]. The results obtained have shown that the
best predictive factor for foetal development is not
a dose of the compound tested but its effect on pan-
creatic function, especially its influence on maternal
glucose levels, and, though less likely, on amylase
activity. In the common DFU-treated group, unlike
the control group, a high glucose level increased the
incidence of foetal overgrowth (macrosomia).
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The data presented above for the influence of the
glucose level on foetal and placental development
partially confirmed the previous animal and human
observations. It was shown that prolonged eleva-
tion of the glucose level, a typical sign of diabetes
and glucose intolerance, may result in foetal over-
growth, as well as higher perinatal mortality, inci-
dence of respiratory distress and congenital devel-
opmental abnormalities such as anencephaly, en-
cephalomeningocoele, caudal regression syndrome,
transposition of the great vessels and coarctation of
the aorta [16, 20, 22]. During uncomplicated preg-
nancy the influence of hypoglycaemic factors is much
stronger than hyperglycaemic ones. In consequence,
higher maternal insulin secretion prevents hypergly-
caemia [19]. However, unlike the normal levels of
adrenal, noradrenaline, growth hormone and glu-
cagons, which remain similar throughout pregnan-
cy, the higher cortisol level correlates with gestational
age. During pregnancy extra placental-relted hyper-
glycaemic factors, such as lactogen (HPL), prolactin,
insulinases (transhydrogenase glutathione insulinase
and sulfhydrylprotease, oestrogens and progester-
one are also synthesised. HPL and prolactin are char-
acterised by the strongest anti-insulin activity and
are blamed for the glucose intolerance [13, 14].
It has also been suggested that during pregnancy
the content of insulin receptors decreases, while the
insulin-binding protein increases significantly [18,
25]. In spite of the constitutive secretion of foetal
insulin at an early developmental stage, the foetus
does not regulate hyperglycaemia by increasing in-
sulin secretion owing to the insufficiency of the ade-
nyl cyclase-dependent pathway. Even later, when
an extra amount of endogenous insulin is secreted,
its total activity cannot normalise the increase in
glucose level, since the main role of foetal insulin is
to regulate growth [19, 27]. Such activity may ex-
plain foetal overgrowth in offspring born to dia-
betic mothers. Furthermore, both clinical observa-
tions in type 1 diabetic pregnancies and prelimi-
nary animal experimental studies suggest that even
short periods of metabolic perturbation early in
pregnancy may affect placental growth and trans-
port functions for the remaining period of preg-
nancy, thereby contributing to foetal overgrowth.
An in vitro simultaneous study has demonstrated
an up-regulation of placental transport systems for
glucose and certain amino acids, as well as placen-
tal lipoprotein lipase. In such a situation an up-reg-
ulation of inflammatory mediators and Leptin genes
is also revealed [19]. However, since none of the
above-mentioned hormones and enzymes was eval-
uated in our study, it is not possible to fully explain
the phenomena observed.
CONCLUSION
In conclusion, it was found that DFU administered
throughout mid and late pregnancy in rats did not
change maternal or foetal pancreatic morphology and
function, or the immunoexpression of constitutive and
inducible cyclooxygenase isoforms in the organ. How-
ever, administration of a COX-2 selective inhibitor may
affect foetal development in a mechanism that is re-
lated to abnormal glucose levels.
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